{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:19:25Z","timestamp":1778721565619,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"APP categories revealed in our study including Olanzapine\/Paliperidone"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ajp.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T20:27:21Z","timestamp":1520713641000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Prevalence and correlates of antipsychotic polypharmacy in Hong Kong"],"prefix":"10.1016","volume":"33","author":[{"given":"Stephanie Lock Man","family":"Lung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Ming Edwin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Hai Eric","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5445-4863","authenticated-orcid":false,"given":"Kit Wa Sherry","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai Ming Christy","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2018.03.012_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/JCP.0b013e31825244f6","article-title":"Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications","volume":"32","author":"Aggarwal","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0924-977X(01)00097-9","article-title":"Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials","volume":"11","author":"Alemen","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0924-977X(02)00079-2","article-title":"Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study","volume":"13","author":"Alvarez","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0025","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2174\/1381612043384033","article-title":"Antipsychotic polypharmacy","volume":"10","author":"Anath","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ajp.2018.03.012_bib0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eurpsy.2005.07.006","article-title":"Randomized clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence","volume":"21","author":"Arrango","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2007-993209","article-title":"Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial","volume":"41","author":"Assion","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-9964(00)90756-4","article-title":"Olanzapine vs. clozapine: side effects and distress in schizophrenic patients","volume":"41","author":"Bajs-Bjegovic","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2018.03.012_bib0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ajp.2018.03.012_bib0050","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1517\/14656566.2011.626769","article-title":"A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia","volume":"13","author":"Citrome","year":"2012","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.ajp.2018.03.012_bib0055","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCP.0000000000000353","article-title":"Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge","volume":"35","author":"Doshi","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","article-title":"Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations","volume":"106","author":"Freudenreich","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ajp.2018.03.012_bib0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials","volume":"28","author":"Fusar-Poli","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970 to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2018.03.012_bib0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.195.52.s20","article-title":"First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia systematic review of randomized controlled trials and observational studies","volume":"195","author":"Haddad","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4088\/JCP.v62n0805","article-title":"Risperidone added to clozapine: impact on serum prolactin levels","volume":"62","author":"Hendersen","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0085","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","volume":"2","author":"Hunter","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2018.03.012_bib0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality","volume":"188","author":"Joukamaa","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia","volume":"8","author":"Kane","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0100","first-page":"155","article-title":"Rational antipsychotic polypharmacy","volume":"7","author":"Kennedy","year":"2000","journal-title":"Can. J. Clin. Pharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","article-title":"Treatment with antipsychotics and the risk of diabetes in clinical practice","volume":"197","author":"Kessing","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/01.jcp.0000245563.06660.0f","article-title":"Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia","volume":"26","author":"Kinon","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0115","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2018.03.012_bib0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.yic.0000188216.92408.69","article-title":"Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study","volume":"21","author":"Kreinin","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2013a critical systematic review and meta-analysis of randomized long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2018.03.012_bib0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ajp.2018.03.012_bib0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/0004867414536931","article-title":"Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China","volume":"49","author":"Li","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0145","first-page":"531","article-title":"Combination of antipsychotics: pros, cons, and questions","volume":"29","author":"Miller","year":"2002","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2018.03.012_bib0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled trials comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2018.03.012_bib0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0447.2004.00356.x","article-title":"Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine","volume":"110","author":"Munro","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ajp.2018.03.012_bib0160","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/schbul\/sbu128","article-title":"Comparative effectiveness of risperidone long-acting injectable vs first generation antipsychotic long-acting injectibles in schizophrenia: results from a nationwide, retrospective inception cohort study","volume":"41","author":"Nielsen","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2018.03.012_bib0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00044011-200828080-00001","article-title":"Practical issues with amisulpride in the management of patients with schizophrenia","volume":"18","author":"Pani","year":"2008","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ajp.2018.03.012_bib0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1503\/jpn.140094","article-title":"Clozapine augmentation with amisulpride","volume":"39","author":"Porcelli","year":"2014","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.ajp.2018.03.012_bib0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/0972-6748.119638","article-title":"Augmenting amisulpride with clozapine to unmasking of akathisia","volume":"21","author":"Ray","year":"2012","journal-title":"Ind. Psychiatry J."},{"key":"10.1016\/j.ajp.2018.03.012_bib0180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.9758\/cpn.2015.13.3.275","article-title":"Antipsychotic prescribing patterns in first-episode schizophrenia: a five-year comparison","volume":"13","author":"Roh","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.ajp.2018.03.012_bib0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","article-title":"Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia","volume":"58","author":"Sim","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0190","first-page":"31","article-title":"Standards of care and clinical algorithms for treating schizophrenia","volume":"60","author":"Smith","year":"1998","journal-title":"Psychiatric Clin. North Am."},{"key":"10.1016\/j.ajp.2018.03.012_bib0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4088\/JCP.v63n0201","article-title":"Antipsychotic polypharmacy: squandering precious resources?","volume":"63","author":"Stahl","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0200","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00127-012-0586-6","article-title":"Description of long-term polypharmacy among schizophrenia outpatients","volume":"48","author":"Suokas","year":"2013","journal-title":"Soc. Psychiatry Psychiatric Epidemiol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0205","series-title":"Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2012"},{"key":"10.1016\/j.ajp.2018.03.012_bib0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic\u2013a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatrica Scand."},{"key":"10.1016\/j.ajp.2018.03.012_bib0215","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0269881105057002","article-title":"The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review","volume":"20","author":"Thronton","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200831010-00002","article-title":"Benefits and risks of antipsychotic polypharmacy","volume":"31","author":"Tranulis","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.ajp.2018.03.012_bib0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.173.4.325","article-title":"Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study","volume":"173","author":"Waddington","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0230","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.pnpbp.2007.01.013","article-title":"Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China","volume":"31","author":"Xiang","year":"2007","journal-title":"Prog. Neuroosychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2018.03.012_bib0235","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-Generation vs first-generation antipsychotics in first episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2018.03.012_bib0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187620181730494X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187620181730494X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:29:22Z","timestamp":1761755362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187620181730494X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":48,"alternative-id":["S187620181730494X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2018.03.012","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and correlates of antipsychotic polypharmacy in Hong Kong","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}